Half-year report · Q2
6523.TEDINET S100UR3H
Period2024-04-01 → 2024-09-30
Filed2024-11-13
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 47
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥173.9bn | 2024-04-01 → 2024-09-30 | Cons. | Revenue IFRS |
| Revenue | ¥353.9bn | 2023-04-01 → 2024-03-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥166.8bn | 2023-04-01 → 2023-09-30 | Cons. | Revenue IFRS |
| Operating income | ¥9.2bn | 2024-04-01 → 2024-09-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥4.2bn | 2023-04-01 → 2023-09-30 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥7.4bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | −¥13.2bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | −¥3.0bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥4.1bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | −¥12.9bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | −¥2.5bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥4.0bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss IFRS |
| Net income | −¥2.4bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss IFRS |
| Total assets | ¥525.4bn | at 2024-09-30 | Cons. | Assets IFRS |
| Total assets | ¥564.3bn | at 2024-03-31 | Cons. | Assets IFRS |
| Total assets | ¥570.4bn | at 2023-09-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥398.0bn | at 2024-09-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥425.2bn | at 2024-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥127.4bn | at 2024-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥139.2bn | at 2024-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥147.0bn | at 2023-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥138.8bn | at 2023-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥127.8bn | at 2024-09-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥139.5bn | at 2024-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥147.4bn | at 2023-09-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥33.0bn | at 2024-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥47.0bn | at 2024-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥61.4bn | at 2023-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥60.9bn | at 2023-03-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥13.8bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥41.3bn | 2023-04-01 → 2024-03-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥22.7bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥5.0bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥21.1bn | 2023-04-01 → 2024-03-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥2.1bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥20.9bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥39.1bn | 2023-04-01 → 2024-03-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥23.6bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥32.52 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥-102.48 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥-19.55 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥32.42 | 2024-04-01 → 2024-09-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥-102.48 | 2023-04-01 → 2024-03-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥-19.55 | 2023-04-01 → 2023-09-30 | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 24.3% | at 2024-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 24.7% | at 2024-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 25.8% | at 2023-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 30
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | ¥1.6bn |
| Reconciling Itemsreconciling | revenue external | 2024-04-01 → 2024-09-30 | ¥1.6bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥4.3bn |
| jpcrp040300-q2r_E36976-000Diabetes Managementreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥48.3bn |
| jpcrp040300-q2r_E36976-000Diabetes Managementreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥48.3bn |
| jpcrp040300-q2r_E36976-000Diabetes Managementreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥6.4bn |
| jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥62.6bn |
| jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥62.6bn |
| jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥3.5bn |
| jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥61.5bn |
| jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥61.5bn |
| jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥3.6bn |
| —segment total | revenue | 2024-04-01 → 2024-09-30 | ¥172.3bn |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥172.3bn |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | ¥13.5bn |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-09-30 | ¥1.1bn |
| Reconciling Itemsreconciling | revenue external | 2023-04-01 → 2023-09-30 | ¥1.1bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-09-30 | −¥4.8bn |
| jpcrp040300-q2r_E36976-000Diabetes Managementreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥48.8bn |
| jpcrp040300-q2r_E36976-000Diabetes Managementreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥48.8bn |
| jpcrp040300-q2r_E36976-000Diabetes Managementreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥5.5bn |
| jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥61.0bn |
| jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥61.0bn |
| jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥2.5bn |
| jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥55.9bn |
| jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥55.9bn |
| jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥951m |
| —segment total | revenue | 2023-04-01 → 2023-09-30 | ¥165.7bn |
| —segment total | revenue external | 2023-04-01 → 2023-09-30 | ¥165.7bn |
| —segment total | segment profit | 2023-04-01 → 2023-09-30 | ¥8.9bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 812
| Item | Context | Value | Unit |
|---|---|---|---|
| Independent auditors report consolidated (text) | FilingDateInstant | Text · Plus | |
| Audit firm1 consolidated | FilingDateInstant | Original text (Japanese)有限責任 あずさ監査法人 | |
| Cpa1 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)花岡 克典 | |
| Cpa2 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)西垣内 琢也 | |
| Number of submission | FilingDateInstant | 1 | |
| Revenue IFRS (5-year summary) | Prior1YTDDuration | 166819000000 | JPY |
| Revenue IFRS (5-year summary) | CurrentYTDDuration | 173863000000 | JPY |
| Revenue IFRS (5-year summary) | Prior1YearDuration | 353900000000 | JPY |
| Profit loss before tax IFRS (5-year summary) | Prior1YTDDuration | -3030000000 | JPY |
| Profit loss before tax IFRS (5-year summary) | CurrentYTDDuration | 7411000000 | JPY |
| Profit loss before tax IFRS (5-year summary) | Prior1YearDuration | -13249000000 | JPY |
| Profit loss attributable to owners of parent IFRS (5-year summary) | Prior1YTDDuration | -2457000000 | JPY |
| Profit loss attributable to owners of parent IFRS (5-year summary) | CurrentYTDDuration | 4100000000 | JPY |
| Profit loss attributable to owners of parent IFRS (5-year summary) | Prior1YearDuration | -12893000000 | JPY |
| Comprehensive income attributable to owners of parent IFRS (5-year summary) | Prior1YTDDuration | 15275000000 | JPY |
| Comprehensive income attributable to owners of parent IFRS (5-year summary) | CurrentYTDDuration | -9563000000 | JPY |
| Comprehensive income attributable to owners of parent IFRS (5-year summary) | Prior1YearDuration | 11878000000 | JPY |
| Equity attributable to owners of parent IFRS (5-year summary) | Prior1QuarterInstant | 147377000000 | JPY |
| Equity attributable to owners of parent IFRS (5-year summary) | CurrentQuarterInstant | 127803000000 | JPY |
| Equity attributable to owners of parent IFRS (5-year summary) | Prior1YearInstant | 139515000000 | JPY |
| Total assets IFRS (5-year summary) | Prior1QuarterInstant | 570443000000 | JPY |
| Total assets IFRS (5-year summary) | CurrentQuarterInstant | 525436000000 | JPY |
| Total assets IFRS (5-year summary) | Prior1YearInstant | 564327000000 | JPY |
| Basic earnings loss per share IFRS (5-year summary) | Prior1YTDDuration | -19.55 | |
| Basic earnings loss per share IFRS (5-year summary) | CurrentYTDDuration | 32.52 | |
| Basic earnings loss per share IFRS (5-year summary) | Prior1YearDuration | -102.48 | |
| Diluted earnings loss per share IFRS (5-year summary) | Prior1YTDDuration | -19.55 | |
| Diluted earnings loss per share IFRS (5-year summary) | CurrentYTDDuration | 32.42 | |
| Diluted earnings loss per share IFRS (5-year summary) | Prior1YearDuration | -102.48 | |
| Ratio of owners equity to gross assets IFRS (5-year summary) | Prior1QuarterInstant | 0.258 | |
| Ratio of owners equity to gross assets IFRS (5-year summary) | CurrentQuarterInstant | 0.243 | |
| Ratio of owners equity to gross assets IFRS (5-year summary) | Prior1YearInstant | 0.247 | |
| Cash flows from used in operating activities IFRS (5-year summary) | Prior1YTDDuration | 22677000000 | JPY |
| Cash flows from used in operating activities IFRS (5-year summary) | CurrentYTDDuration | 13767000000 | JPY |
| Cash flows from used in operating activities IFRS (5-year summary) | Prior1YearDuration | 41304000000 | JPY |
| Cash flows from used in investing activities IFRS (5-year summary) | Prior1YTDDuration | -2125000000 | JPY |
| Cash flows from used in investing activities IFRS (5-year summary) | CurrentYTDDuration | -4983000000 | JPY |
| Cash flows from used in investing activities IFRS (5-year summary) | Prior1YearDuration | -21072000000 | JPY |
| Cash flows from used in financing activities IFRS (5-year summary) | Prior1YTDDuration | -23613000000 | JPY |
| Cash flows from used in financing activities IFRS (5-year summary) | CurrentYTDDuration | -20920000000 | JPY |
| Cash flows from used in financing activities IFRS (5-year summary) | Prior1YearDuration | -39139000000 | JPY |
| Cash and cash equivalents IFRS (5-year summary) | Prior1QuarterInstant | 61437000000 | JPY |
| Cash and cash equivalents IFRS (5-year summary) | CurrentQuarterInstant | 32969000000 | JPY |
| Cash and cash equivalents IFRS (5-year summary) | Prior1YearInstant | 47044000000 | JPY |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 126344428 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 126344872 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 126344428 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 126344872 | |
| Number of shares held | CurrentQuarterInstant_No1MajorShareholdersMember | 47994000 | |
| Shareholding ratio | CurrentQuarterInstant_No1MajorShareholdersMember | 0.3805 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |